This series examines the EU Pharma Package through the decisions involved in developing, licensing and supplying medicines. Articles cover exclusivity, filing strategy, market access, generic and biosimilar entry, antimicrobial incentives, novel therapies and supply arrangements.
These articles provide general information and are not legal advice.
The EU Pharma Package replaces the 8+2(+1) regime with an 8+1 baseline, mutually exclusive conditional extensions capped at eleven years, and orphan exclusivity recoded onto the active substance. The qualifying choices are fixed years before a US sponsor files.
Two of the four 12-month extensions of EU market protection require the EU filing to come first or within 90 days of the first filing outside the Union. A US sponsor that files with the FDA first and in the EU more than 90 days later loses both.
EU orphan exclusivity will run on one clock per holder and active substance, and new orphan indications can extend it by a year at most twice. The two-year pediatric orphan reward will end, and earnouts keyed to orphan exclusivity will track a changed right.
Art. 56a of the EU Pharma Package Directive lets a Member State demand a launch; non-compliance can strip regulatory market protection in that territory. For US originators, selective EU launch strategy now carries a direct exclusivity cost.
Art. 85 of the EU Pharma Package Directive extends the Bolar exemption to health technology assessment, pricing and reimbursement, and tender filings. Generics and biosimilars can be launch-ready at patent expiry, so US originators may lose EU revenue sooner.
The transferable voucher adds a year of EU data protection, usable on another product only if its annual EU sales stayed within EUR 490 million in its first four years. For most US developers working on antimicrobial resistance (AMR) it is unlikely, alone, to reverse the build-or-abandon decision.
For antimicrobials, the EU Pharma Package extends environmental risk assessment to active-ingredient sites outside the EU. Unaddressed risks can lead to refusal or revocation of the marketing authorization. Supplier contracts rarely secure the effluent data.
A statutory sandbox in the EU Pharma Package lets the Commission adapt authorization requirements for products that cannot meet the standard rules, such as cell and gene therapies and AI-enabled medicines. FDA expedited programs speed a fixed pathway; the sandbox changes the requirements themselves.
Shortage prevention plans and a Union list of critical medicines become standing law, while joint antimicrobial procurement stays voluntary. The duties fall on whoever holds the marketing authorization, whether a US sponsor's EU subsidiary or its distributor.
The EU Pharma Package turns the hospital exemption for cell and gene therapies from a national carve-out into an approval notified to the EMA, with annual data on use, safety and efficacy, while Switzerland drafts a narrower exemption of its own.
After the EU Pharma Package, a biosimilar entrant plans against an 8+1-year baseline whose added years depend on the originator's own applications, and a launch bar that can lift in one Member State. Switzerland runs a separate ten-year clock.
The proposed Biotech Act SPC year would depend on product innovation, efficacy trials in at least three EU states and eligible EU manufacturing. US and Swiss sponsors face unsettled conditions, timing and certificate questions.
The proposed Critical Medicines Act would favor EU manufacturing in certain tenders. For Swiss and US production, the treaty question turns on the goods, supplier, buyer and procurement coverage.
For advice on a particular matter, please get in touch.
Make an enquiry